@attralus

Clinical Stage Biotech Company focused on improving the lives of systemic amyloidosis patients

 Naples, FL
attralus.com
Joined July 2019
  • Tweets164
  • Following376
  • Followers345
74Media
Replying to @Bayer
@Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus. Read the press release: attralus.com/press-releases/…. #amyloidosis
3
7
374
U.S. FDA grants Fast Track designation to zamubafusp alfa (AT-02) for the treatment of light chain (AL)-associated amyloidosis. Read the full announcement: attralus.com/press-releases/… #Amyloidosis #RareDisease #ClinicalResearch
Attralus announcement graphic stating that the U.S. FDA has granted Fast Track designation to zamubafusp alfa (AT-02) for the treatment of AL amyloidosis. Includes the Attralus logo and patient imagery.

ALT Attralus announcement graphic stating that the U.S. FDA has granted Fast Track designation to zamubafusp alfa (AT-02) for the treatment of AL amyloidosis. Includes the Attralus logo and patient imagery.

2
3
285
Attralus announced FDA orphan drug designation for zamubafusp alfa (AT-02) in AL amyloidosis, a rare, progressive disease. Read more 👉 attralus.com/press-releases/… #Amyloidosis #ALAmyloidosis #RareDisease #OrphanDrug #FDA
Graphic with Attralus logo and text announcing that zamubafusp alfa (AT‑02) received U.S. FDA orphan drug designation for AL amyloidosis, alongside a collage of patient portraits.

ALT Graphic with Attralus logo and text announcing that zamubafusp alfa (AT‑02) received U.S. FDA orphan drug designation for AL amyloidosis, alongside a collage of patient portraits.

2
6
152
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at #ASH2025. Read the press release: attralus.com/press-releases/… #amyloidosis
3
5
201
Attralus presents new Data on its pan-amyloid diagnostic imaging candidates at #ASNC2025. Read the press release: attralus.com/press-releases/… #amyloidosis
4
9
564
Attralus presents new data on our pan-amyloid diagnostic candidates at #ACC2025. Read the press release: attralus.com/press-releases/… #amyloidosis
1
4
8
309
Attralus announces enrollment of first patient in Phase 3 trial for the pan-amyloid diagnostic 124I-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
2
7
3
17
5,367
Attralus receives Orphan Drug Designation from @US_FDA for AT-02 for the treatment of ATTR #amyloidosis. Read the press release: attralus.com/press-releases/…
7
15
656
Attralus is excited to announce that we have received Breakthrough Therapy Designation for our pan-amyloid diagnostic PET imaging candidate I124-evuzamitide (AT-01) for cardiac #amyloidosis. Read the press release: attralus.com/press-releases/….
3
9
2
25
4,313
Attralus receives EMA Committee for Orphan Medicinal Products positive opinions for AT-02 for treatment of both ATTR and AL #amyloidosis. Read the press release: attralus.com/press-releases/…
4
5
298
Attralus Presents New Data on Its Pan-Amyloid Therapeutic and Diagnostic Candidates at #ISA2024. Read the press release at attralus.com/press-releases/…. #amyloidosis
4
10
358
Looking forward to @ISA_Amyloidosis #ISA_2024 in Rochester, MN on 26-30 May. We are proud to announce 16 presentations, incl 3 oral presentations, highlighting our investigational agents and continued commitment to #amyloidosis patients. Learn more: attralus.com.
2
1
15
3,512
On #raredisease day we honor rare disease patients waiting for new treatments, the patient advocacy groups and healthcare providers working tirelessly to improve patients' lives, and especially the many #amyloidosis patients as they battle with this rare and devastating disease.
5
154
We are excited to announce the closing of our $56 million financing. Read more: attralus.com/press-releases/… #amyloidosis
5
117
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging) #JACCIMG Read more - attralus.com/press-releases/… #amyloidosis
Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

ALT Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

9
356
Attralus Announces Presentation of Clinical Data for 124I-Evuzamitide (AT-01), a Novel Amyloid-Specific PET Imaging Agent, at #ASNC2023 Read more - attralus.com/press-releases/… #amyloidosis
7
13
1,115
For #NationalAmyloidosisDay, a reminder that #amyloidosis is a #raredisease that is progressive and debilitating, and as many as 80% of patients worldwide go undiagnosed or wait years to receive a diagnosis. Learn more about systemic #amyloidosis @ ow.ly/62CK50J2aZ1.
2
1
1
722
Attralus retweeted
Alzforum@alzforum3 May 2023
New ways to target pathologic tau focus on intracellular tau, vaccines, and multivalent molecules that attack several types of fibril. #alzheimersdisease ow.ly/YgGo50Ofh39
7
26
3,461
Attralus' experimental therapies, AT-04 and AT-07, are able to bind to proteins causing toxic clumps in Parkinson's, suggesting new treatment possibilities. buff.ly/3nSvs7V #parkinsonsdiseaseresearch #parkinsonsdisease #livingwithparkinsons
2
8
295
Informative video from Dr. Jonathan Wall of @attralus describing their work to develop non-invasive imaging to diagnose amyloid deposits. Great stuff. #amyloidosis youtube.com/watch?v=7hDLbRiU…

New Method to Potentially Diagnose Amyloidosis

Jonathan Wall, PhD, Director of the University of Tennessee Graduat...

youtube.com
1
6
11
660
New preclinical data on AT-04 and AT-07, our pan-amyloid removal therapeutics targeting neurodegenerative disorders was presented this past weekend at #ADPD2023. Read more attralus.com/press-releases/… #amyloidosis #AlzheimersDisease
2
3
10
775
Load more